Clinical trial NCT04914286: A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Official title: A Multi-center, Single-arm, and Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH018 in Combination With Toripalimab in the Treatment of Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Advanced Solid Tumor
Lead sponsor: Genfleet Therapeutics (Shanghai) Inc.
Sponsor class: INDUSTRY
First posted: 2021-06-04
Enrollment: 148
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the safety/tolerability, pharmacokinetics, and preliminary efficacy of GFH018 in combination with Toripalimab in patients with advanced solid tumors.


Eligibility criteria: Inclusion Criteria:

1. Has histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumors, progressed on at least first line therapy.
2. Has sufficient organ functions.
3. Eastern Cooperative Oncology Group Performance Status (ECOG P.S.) ≤ 1. Subject with tumor involvement of the liver must have the Child-Pugh score of 0-7.
4. Life expectancy≥12 weeks.
5. Female or male subjects of child-bearing potential must agree to use effective contraceptive methods from the signing of the informed consent to 90 days after the last administration of the study drug. Fertile female subjects must have negative pregnancy test results within 7 days (inclusive) before administration.

In addition, eligible patients in phase II part must meet the following criteria:

1. Histologically or cytologically confirmed diagnosis of unresectable or metastatic advanced tumors of specific types: hepatocellular carcinoma, cholangiocarcinoma/gallbladder cancer (except carcinoma of ampulla), pancreatic cancer, colorectal cancer, urothelium carcinoma, cervical cancer, head and neck squamous cell carcinoma, esophageal cancer and nasopharyngeal carcinoma.
2. At least one measurable lesion (according to RECIST 1.1).

Exclusion Criteria:

1. Impaired cardiac function or clinically significant cardiac diseases.
2. With acute or chronic infections.
3. With active central nervous system metastases, including symptomatic brain metastases, meningeal metastases, spinal cord compression, or requiring treatment with glucocorticoids, antiepileptic drugs, anticonvulsant drugs, or mannitol.
4. With known active autoimmune diseases or a history of autoimmune diseases within 1 year prior to enrollment.
5. With clinically significant gastrointestinal diseases.
6. Uncontrollable or symptomatic ascites, pleural effusion or pericardial effusion.
7. With previous or present interstitial pneumonia.
8. With other uncontrolled systemic diseases, such as hypertension and diabetes.
9. Diagnosed with other malignant tumors within 3 years prior to starting study drug, except for cured carcinoma in situ of cervix and skin basal cell carcinoma.
10. With diseases requiring immunosuppressant therapy, or requiring prednisone \> 10 mg/day or equivalent dose of similar drugs during the study period.
11. Subjects who have been treated with immunosuppressant drugs within 28 days prior to starting study drug, except for topical and inhaled cortisol and systemic cortisol of physiological dose (prednisone \< 10 mg/day or equivalent dose of similar drugs).
12. Subjects who have received live vaccine, attenuated vaccine within 28 days prior to starting study drug, or plans to receive live vaccine, attenuated vaccine during treatment or within 30 days after the last administration.
13. Subjects who have been treated with radiotherapy, chemotherapy, targeted therapy, endocrine therapy, immunotherapy, and other anti-tumor therapies, or other investigational drugs within 5 half-life periods or within 28 days (whichever is shorter) prior to starting study drug.
14. Subject who has received major surgeries (except for needle biopsy) that may affect the administration or study evaluation within 28 days prior to starting study drug.
15. Subjects who have received strong inhibitor or inducer of CYP3A4, or herbal medicine/traditional Chinese medicines within 5 half-life periods or within 2 weeks (whichever is shorter) prior to starting study drug.
16. Subjects who have received combined treatment of drugs targeting TGF-β and PD-(L)1, including combination of antibody and small molecule or bispecific antibody.
17. Pregnant or lactating women.

Primary outcomes:
measure: Phase Ib：Incidence of dose-limiting toxicity (DLT) events
timeFrame: 28 days
measure: Phase II: ORR (Objective Response Rate)
timeFrame: approximately 6 months after first dose
Secondary outcomes:
Other outcomes:
Locations:
city: Perth
country: Australia
facility: Linear Clinical Research Ltd
state: Western Australia
city: Guangzhou
country: China
facility: Sun Yat-sen university cancer center
state: Guangdong
city: Shanghai
country: China
facility: Shang hai east hospital
state: Shanghai
Study officials:
References: